We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Method for Accurately Assessing the Latent Virus Reservoir in Chronic HIV Patients

By LabMedica International staff writers
Posted on 20 Apr 2021
A modified version of the PCR test can determine the quantity and quality of inactive human immunodeficiency virus (HIV) in the genes of individuals suffering from chronic HIV.

While HIV is not curable, antiretroviral therapy drugs (ARTs) effectively suppress the HIV virus to undetectable levels. More...
Nonetheless, a latent HIV reservoir persists due to HIV's integration into the host DNA, specifically in the chromosomes of T lymphocytes and macrophages. Quantifying this replication-competent HIV reservoir is essential for evaluating prognostic and curative strategies.

Currently used viral outgrowth assays (VOAs) underestimate the reservoir because they fail to induce all replication-competent proviruses. Single- or double-region HIV DNA assays overestimate it because they fail to exclude many defective proviruses.

To correct for the over and under estimation of the latent HIV reservoir, investigators at the University of Washington (Seattle, USA) designed two triplex droplet digital PCR (ddPCR) assays, each with two unique targets and one in common, and normalized the results to PCR-based T-cell counts.

The classical PCR test carries out one reaction per single sample. The digital PCR (dPCR) method also carries out a single reaction within a sample, however the sample is separated into a large number of partitions and the reaction is carried out in each partition individually. This separation allows a more reliable collection and sensitive measurement of nucleic acid amounts. The dPCR method has been demonstrated as useful for studying variations in gene sequences - such as copy number variants and point mutations - and it is routinely used for clonal amplification of samples for next-generation sequencing.

Droplet digital PCR (ddPCR) is a variation of dPCR in which a 20 microliter sample reaction including assay primers and either Taqman probes or an intercalating dye, is divided into about 20,000 nanoliter-sized oil droplets through a water-oil emulsion technique, thermocycled to endpoint in a 96-well PCR plate, and fluorescence amplitude read for all droplets in each sample well in a droplet flow cytometer.

A ddPCR assay protocol reported in 2019 probed two regions of the HIV-1 genome within each droplet. For the current study, the investigators used two three-region (triplex) ddPCR assays to develop a five-region test (one overlapping region allowed inter-assay quality control). They referred to triple-positive ddPCR droplets as “potentially intact.” By combining the two parallel triplex assays, they could confidently quantify truly intact HIV-1 viral genomes. As a further enhancement, they adapted a multiplexed ddPCR assay specifically quantifying T-cells to accurately normalize to the number of HIV target cells interrogated. This additional step was especially useful for tissue biopsies, because, in contrast to blood, cell populations in tissues were difficult to isolate and purify.

Results obtained during this study revealed that both HIV ddPCR assays were specific, sensitive, and reproducible. Together, they estimated the number of proviruses containing all five primer-probe regions. The five-target results were on average 12.1-fold higher than and correlated with paired quantitative VOA but estimated a markedly smaller reservoir than previous DNA assays.

"Our laboratory test is a simpler way to quantify the reservoir of intact viruses," said senior author Dr. Florian Hladik, research professor of obstetrics and gynecology at the University of Washington. "I can see a patient going to a doctor and adding this to the list of questions they might ask. Now they ask about their viral load and T-cell count. I hope in the future they may be able to ask how large their HIV reservoir might be. What gets me excited is that one day, this number may tell them how long it will take to entirely eliminate HIV from their body."

The study was published in the April 12, 2021, online edition of the journal Cell Reports Medicine.

Related Links:
University of Washington


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Immunofluorescence Analyzer
IFA System
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.